Log in

Intercept Pharmaceuticals News Headlines (NASDAQ:ICPT)

$94.99
+1.08 (+1.15 %)
(As of 02/24/2020 01:29 AM ET)
Today's Range
$93.87
Now: $94.99
$97.73
50-Day Range
$92.28
MA: $101.67
$117.54
52-Week Range
$56.76
Now: $94.99
$125.00
Volume510,595 shs
Average Volume370,259 shs
Market Capitalization$3.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.74

Headlines

Intercept Pharmaceuticals (NASDAQ ICPT) News Headlines

Source:
DateHeadline
Intercept Pharmaceuticals (NASDAQ:ICPT) Upgraded to "Market Perform" at Leerink SwannIntercept Pharmaceuticals (NASDAQ:ICPT) Upgraded to "Market Perform" at Leerink Swann
www.americanbankingnews.com - February 21 at 11:52 AM
Intercept Pharmaceuticals (NASDAQ:ICPT) Raised to Market Perform at Svb LeerinkIntercept Pharmaceuticals (NASDAQ:ICPT) Raised to Market Perform at Svb Leerink
www.americanbankingnews.com - February 21 at 11:05 AM
Intercept Pharmaceuticals (NASDAQ:ICPT) Given Buy Rating at B. RileyIntercept Pharmaceuticals (NASDAQ:ICPT) Given Buy Rating at B. Riley
www.americanbankingnews.com - February 21 at 7:08 AM
Inside the $3 billion biotech preparing to launch the first treatment for NASH, a silent disease that affects millions of AmericansInside the $3 billion biotech preparing to launch the first treatment for NASH, a silent disease that affects millions of Americans
www.businessinsider.com - February 19 at 12:44 PM
Intercept Pharmaceuticals (ICPT) to Release Quarterly Earnings on TuesdayIntercept Pharmaceuticals (ICPT) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 19 at 10:49 AM
Intercept to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020Intercept to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
finance.yahoo.com - February 18 at 9:08 AM
Intercept Pharmaceuticals, Inc. Common Stock (ICPT) Revenue EPSIntercept Pharmaceuticals, Inc. Common Stock (ICPT) Revenue EPS
www.nasdaq.com - February 16 at 11:26 PM
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Short Interest UpdateIntercept Pharmaceuticals Inc (NASDAQ:ICPT) Short Interest Update
www.americanbankingnews.com - February 15 at 12:20 AM
Intercept Pharmaceuticals, Inc. Common Stock (ICPT) Institutional HoldingsIntercept Pharmaceuticals, Inc. Common Stock (ICPT) Institutional Holdings
www.nasdaq.com - February 14 at 12:22 AM
Intercept Pharmaceuticals (NASDAQ:ICPT) Earns Buy Rating from WedbushIntercept Pharmaceuticals (NASDAQ:ICPT) Earns Buy Rating from Wedbush
www.americanbankingnews.com - February 10 at 6:34 AM
Notable Wednesday Option Activity: ICPT, NVRO, ONBNotable Wednesday Option Activity: ICPT, NVRO, ONB
www.nasdaq.com - February 5 at 7:27 PM
13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market
finance.yahoo.com - February 5 at 7:27 PM
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Receives Average Rating of "Buy" from AnalystsIntercept Pharmaceuticals Inc (NASDAQ:ICPT) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - February 4 at 8:01 PM
Is Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) CEO Salary Justified?Is Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) CEO Salary Justified?
finance.yahoo.com - February 3 at 1:45 PM
Intercept Pharmaceuticals (ICPT) "Buy" Rating Reiterated at WedbushIntercept Pharmaceuticals' (ICPT) "Buy" Rating Reiterated at Wedbush
www.americanbankingnews.com - January 30 at 7:02 AM
Better Buy: Intercept Pharmaceuticals vs. Gilead SciencesBetter Buy: Intercept Pharmaceuticals vs. Gilead Sciences
www.fool.com - January 30 at 6:34 AM
Intercept Pharma completes enrollment in late-stage NASH studyIntercept Pharma completes enrollment in late-stage NASH study
seekingalpha.com - January 29 at 1:23 PM
Intercept Completes Enrollment of Phase 3 REVERSE Study Evaluating Obeticholic Acid for the Treatment of Compensated Cirrhosis due to NASHIntercept Completes Enrollment of Phase 3 REVERSE Study Evaluating Obeticholic Acid for the Treatment of Compensated Cirrhosis due to NASH
finance.yahoo.com - January 29 at 8:23 AM
Interesting ICPT Put And Call Options For September 18thInteresting ICPT Put And Call Options For September 18th
www.nasdaq.com - January 23 at 5:29 PM
Where Will Intercept Pharmaceuticals Be in 5 Years?Where Will Intercept Pharmaceuticals Be in 5 Years?
www.fool.com - January 23 at 12:58 PM
2 Mid-Cap Biotech Stocks to Buy Right Now2 Mid-Cap Biotech Stocks to Buy Right Now
www.fool.com - January 22 at 1:37 PM
FDA Decision For Intercepts NASH Drug Ocaliva Delayed; Opportunity Presents ItselfFDA Decision For Intercept's NASH Drug Ocaliva Delayed; Opportunity Presents Itself
seekingalpha.com - January 20 at 6:22 PM
3 Biotech Stocks to Bank on for Buyouts in 20203 Biotech Stocks to Bank on for Buyouts in 2020
finance.yahoo.com - January 18 at 9:39 AM
Intercept to Present at the 38th Annual J.P. Morgan Healthcare ConferenceIntercept to Present at the 38th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 8 at 4:13 PM
Analysts Expect Breakeven For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)Analysts Expect Breakeven For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
finance.yahoo.com - January 2 at 4:42 PM
Intercept Pharma Has a New Liver Drug. Don’t Expect FDA Approval to Lift the Stock, Analyst Says.Intercept Pharma Has a New Liver Drug. Don’t Expect FDA Approval to Lift the Stock, Analyst Says.
finance.yahoo.com - January 2 at 4:42 PM
Citi Downgrades Intercept, Says NASH Launch Is Appropriately Priced InCiti Downgrades Intercept, Says NASH Launch Is Appropriately Priced In
finance.yahoo.com - January 2 at 4:42 PM
XBI, ICPT, SGEN, ALNY: Large Inflows Detected at ETFXBI, ICPT, SGEN, ALNY: Large Inflows Detected at ETF
www.nasdaq.com - December 27 at 12:51 PM
Pharma Companies Are Rushing to Treat a Little-Known Liver Disease. Investors Should Be Skeptical.Pharma Companies Are Rushing to Treat a Little-Known Liver Disease. Investors Should Be Skeptical.
finance.yahoo.com - December 26 at 7:23 AM
Why the 2020 NASH Revolution Could Prove UnderwhelmingWhy the 2020 NASH Revolution Could Prove Underwhelming
finance.yahoo.com - December 24 at 2:00 PM
Gilead (GILD) Announces Top-Line Results From NASH StudyGilead (GILD) Announces Top-Line Results From NASH Study
finance.yahoo.com - December 17 at 12:53 PM
Intercept: History May Repeat ItselfIntercept: History May Repeat Itself
seekingalpha.com - December 17 at 7:38 AM
Intercept Pharma files European application for OCA, U.S. Ad Com setIntercept Pharma files European application for OCA, U.S. Ad Com set
seekingalpha.com - December 13 at 8:27 AM
Intercept Provides Regulatory UpdateIntercept Provides Regulatory Update
finance.yahoo.com - December 13 at 8:27 AM
Intercept Pharmaceuticals: Blockbuster Therapy Unveils An Upside CatalystIntercept Pharmaceuticals: Blockbuster Therapy Unveils An Upside Catalyst
seekingalpha.com - December 10 at 3:45 PM
Heres Why Intercept Pharmaceuticals Stock Rose 48.9% in NovemberHere's Why Intercept Pharmaceuticals Stock Rose 48.9% in November
www.fool.com - December 10 at 8:34 AM
Intercept to Host NASH Commercial Day for Investors on December 16, 2019 in New YorkIntercept to Host NASH Commercial Day for Investors on December 16, 2019 in New York
finance.yahoo.com - December 10 at 8:33 AM
Notable Monday Option Activity: V, ICPT, AYINotable Monday Option Activity: V, ICPT, AYI
www.nasdaq.com - December 9 at 6:20 PM
January 2020 Options Now Available For Intercept Pharmaceuticals (ICPT)January 2020 Options Now Available For Intercept Pharmaceuticals (ICPT)
www.nasdaq.com - December 6 at 2:18 PM
Intercept Announces Publication of Results from...Intercept Announces Publication of Results from...
www.benzinga.com - December 5 at 11:05 PM
Intercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The LancetIntercept Announces Publication of Results from the Interim Analysis of the Phase 3 REGENERATE Study of OCA for the Treatment of Fibrosis Due to NASH in The Lancet
finance.yahoo.com - December 5 at 11:05 PM
Intercept (ICPT) Up 48.6% Since Last Earnings Report: Can It Continue?Intercept (ICPT) Up 48.6% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - December 5 at 1:04 PM
Is Intercept Pharmaceuticals (NASDAQ:ICPT) Using Debt In A Risky Way?Is Intercept Pharmaceuticals (NASDAQ:ICPT) Using Debt In A Risky Way?
finance.yahoo.com - December 3 at 7:49 AM
Intercept Pharmaceuticals Appoints Jason Campagna as Chief Medical OfficerIntercept Pharmaceuticals Appoints Jason Campagna as Chief Medical Officer
finance.yahoo.com - December 2 at 9:15 AM
Edited Transcript of ICPT earnings conference call or presentation 5-Nov-19 1:30pm GMTEdited Transcript of ICPT earnings conference call or presentation 5-Nov-19 1:30pm GMT
finance.yahoo.com - November 11 at 2:31 PM
New REGENERATE Interim Analysis Data Presented at The Liver Meeting® Report OCA Improved Multiple Noninvasive Markers of Liver Fibrosis in Patients with NASHNew REGENERATE Interim Analysis Data Presented at The Liver Meeting® Report OCA Improved Multiple Noninvasive Markers of Liver Fibrosis in Patients with NASH
finance.yahoo.com - November 8 at 7:36 AM
BRIEF-Intercept Pharmaceuticals Reports Q3 Revenue $61.9 MlnBRIEF-Intercept Pharmaceuticals Reports Q3 Revenue $61.9 Mln
www.msn.com - November 5 at 7:37 PM
Intercept Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call PresentationIntercept Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call Presentation
seekingalpha.com - November 5 at 2:37 PM
Intercept Pharmaceuticals Inc (ICPT) Q3 2019 Earnings Call TranscriptIntercept Pharmaceuticals Inc (ICPT) Q3 2019 Earnings Call Transcript
www.nasdaq.com - November 5 at 2:37 PM
Intercept Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business UpdateIntercept Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
finance.yahoo.com - November 5 at 9:36 AM
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: What are economic reports?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel